---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-071385"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2023-06-15T23:59:59+00:00"
generated_at: "2026-06-14T00:27:44.419511+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Oncology Institute authorizes up to 5M share buyback at ≤$0.75; obtains lender consent

## Summary
- Board approved repurchase of up to 5M shares of common stock at price not exceeding $0.75 per share.
- Company entered Limited Consent with Deerfield to permit repurchases on or before June 16, 2023, at same price cap.
- Repurchases may be made in open market or negotiated purchases; no obligation to repurchase any shares.
- Limited Consent also waives certain notice requirements under the Facility Agreement.

## SEC filing metadata
- accession: 0001104659-23-071385
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2023-06-15T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000110465923071385/0001104659-23-071385-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000110465923071385/tm2318791d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-071385
- JSON: https://secwatch.observer/filing/0001104659-23-071385.json
- Plain text: https://secwatch.observer/filing/0001104659-23-071385.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.